Lage J M, Weinberg D S, Huettner P C, Mark S D
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Cancer. 1992 Jun 1;69(11):2668-75. doi: 10.1002/1097-0142(19920601)69:11<2668::aid-cncr2820691108>3.0.co;2-n.
The authors undertook a prospective, flow cytometric study of nuclear DNA ploidy in 140 fresh ovarian tumors. There were 43 benign tumors, 27 borderline tumors, and 70 malignant tumors. Results of DNA ploidy analysis were compared to age at diagnosis, menopausal status, tumor size, histologic type, grade, and International Federation of Gynecology and Obstetrics (FIGO) stage. Although the majority of benign tumors were diploid, 19% were aneuploid. Among the benign tumors, DNA ploidy was significantly associated with tumor type and tumor size. All borderline tumors were diploid. Of the 70 malignant tumors, 64% were aneuploid. In the malignant tumors, DNA aneuploidy had significant univariate associations with histologic type, grade, and FIGO stage. By multivariate analysis, DNA aneuploidy remained significantly associated with stage and grade, both known predictors of survival in ovarian cancer. These results indicate that DNA ploidy varies with the aggressive potential of an ovarian cancer and may, at the time of initial diagnosis, provide additional information about tumor prognosis.
作者对140例新鲜卵巢肿瘤进行了一项前瞻性流式细胞术核DNA倍体研究。其中有43例良性肿瘤、27例交界性肿瘤和70例恶性肿瘤。将DNA倍体分析结果与诊断时的年龄、绝经状态、肿瘤大小、组织学类型、分级以及国际妇产科联盟(FIGO)分期进行了比较。虽然大多数良性肿瘤为二倍体,但19%为非整倍体。在良性肿瘤中,DNA倍体与肿瘤类型和肿瘤大小显著相关。所有交界性肿瘤均为二倍体。在70例恶性肿瘤中,64%为非整倍体。在恶性肿瘤中,DNA非整倍体在单因素分析中与组织学类型、分级和FIGO分期显著相关。通过多因素分析,DNA非整倍体仍与分期和分级显著相关,而分期和分级都是卵巢癌已知的生存预测因素。这些结果表明,DNA倍体随卵巢癌的侵袭潜能而变化,并且在初次诊断时可能提供有关肿瘤预后的额外信息。